DK1758565T3 - Fremgangsm de til identifikation af GLP-1-sekretionsfremkaldende stoffer - Google Patents

Fremgangsm de til identifikation af GLP-1-sekretionsfremkaldende stoffer

Info

Publication number: DK1758565T3
Authority: DK; Denmark
Prior art keywords: procedure; identifying glp; inducers; secretion; secretion inducers
Prior art date: 2005-01-10

Application number

DK06717678T

Other languages

English (en)

Other versions

DK1758565T4 (da

Inventor

James N Leonard

Hussien A Al-Shamma

Robert M Jones

Zhi-Liang Chu

Original Assignee

Arena Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-01-10

Filing date

2006-01-09

Publication date

2009-09-07

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36570727&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1758565(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-01-09 Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc

2009-09-07 Publication of DK1758565T3 publication Critical patent/DK1758565T3/da

2013-02-04 Application granted granted Critical

2013-02-04 Publication of DK1758565T4 publication Critical patent/DK1758565T4/da

Links

102100025101 GATA-type zinc finger protein 1 Human genes 0.000 title 1
101710198884 GATA-type zinc finger protein 1 Proteins 0.000 title 1
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title 1
239000000411 inducer Substances 0.000 title 1
230000028327 secretion Effects 0.000 title 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/76—Human chorionic gonadotropin including luteinising hormone, follicle stimulating hormone, thyroid stimulating hormone or their receptors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2857—Seizure disorders; Epilepsy
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Endocrinology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Diabetes (AREA)
Physics & Mathematics (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Cell Biology (AREA)
Biotechnology (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Biochemistry (AREA)
Analytical Chemistry (AREA)
Obesity (AREA)
Microbiology (AREA)
Food Science & Technology (AREA)
Ophthalmology & Optometry (AREA)
Reproductive Health (AREA)
Psychology (AREA)

DK06717678.4T 2005-01-10 2006-01-09 Fremgangsmåde til identifikation af GLP-1-sekretionsfremkaldende stoffer. DK1758565T4 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US64308605P	2005-01-10	2005-01-10
US68317205P	2005-05-19	2005-05-19
US72688005P	2005-10-14	2005-10-14
PCT/US2006/000510 WO2006076231A2 (en)	2005-01-10	2006-01-09	Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level

Publications (2)

Publication Number	Publication Date
DK1758565T3 true DK1758565T3 (da)	2009-09-07
DK1758565T4 DK1758565T4 (da)	2013-02-04

Family

ID=36570727

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK07004743T DK1808168T3 (da)	2005-01-10	2006-01-09	Kombinationsterapi til behandling af diabetes og tilstande relateret hertil og til behandling af tilstande, der lindres ved at öge et blod-GLP-1-niveau
DK06717678.4T DK1758565T4 (da)	2005-01-10	2006-01-09	Fremgangsmåde til identifikation af GLP-1-sekretionsfremkaldende stoffer.

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK07004743T DK1808168T3 (da)	2005-01-10	2006-01-09	Kombinationsterapi til behandling af diabetes og tilstande relateret hertil og til behandling af tilstande, der lindres ved at öge et blod-GLP-1-niveau

Country Status (35)

Country	Link
US (12)	US20060154866A1 (da)
EP (9)	EP1808168B1 (da)
JP (8)	JP4118323B1 (da)
KR (5)	KR101016890B1 (da)
CN (2)	CN102218141A (da)
AR (1)	AR052082A1 (da)
AT (2)	ATE431139T1 (da)
AU (3)	AU2006205164B2 (da)
BR (1)	BRPI0606727A (da)
CA (2)	CA2593427C (da)
CL (1)	CL2010000565A1 (da)
CR (1)	CR9220A (da)
CY (2)	CY1109260T1 (da)
DE (2)	DE602006006765D1 (da)
DK (2)	DK1808168T3 (da)
DO (2)	DOP2006000008A (da)
EA (1)	EA011883B1 (da)
ES (2)	ES2327268T5 (da)
GT (1)	GT200600004A (da)
HN (1)	HN2006000971A (da)
HR (2)	HRP20090403T4 (da)
IL (1)	IL184364A0 (da)
MX (1)	MX2007008376A (da)
NI (1)	NI200700174A (da)
NO (2)	NO331089B1 (da)
NZ (4)	NZ578504A (da)
PA (1)	PA8659301A1 (da)
PE (2)	PE20061116A1 (da)
PL (2)	PL1758565T5 (da)
PT (2)	PT1808168E (da)
RS (2)	RS51127B (da)
SG (2)	SG158876A1 (da)
SI (2)	SI1808168T1 (da)
TW (1)	TW200637534A (da)
WO (1)	WO2006076231A2 (da)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR100926247B1 (ko) *	2001-02-24	2009-11-12	베링거 잉겔하임 파르마 게엠베하 운트 코 카게	크산틴 유도체를 포함하는 약제학적 조성물 및 이의제조방법
EP1411968B1 (en)	2001-07-31	2008-09-17	THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES	Glp-1 exendin-4 peptide analogs and uses thereof
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
MXPA05007485A (es)	2003-01-14	2006-01-30	Arena Pharm Inc	Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
AR045047A1 (es) *	2003-07-11	2005-10-12	Arena Pharm Inc	Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
US7132426B2 (en)	2003-07-14	2006-11-07	Arena Pharmaceuticals, Inc.	Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US7501426B2 (en)	2004-02-18	2009-03-10	Boehringer Ingelheim International Gmbh	8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
EP1838311A1 (en) *	2004-12-24	2007-10-03	Prosidion Limited	G-protein coupled receptor (gpr116) agonists and use thereof for treating obesity and diabetes
DOP2006000008A (es) *	2005-01-10	2006-08-31	Arena Pharm Inc	Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
MY148521A (en) *	2005-01-10	2013-04-30	Arena Pharm Inc	Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
JP5774264B2 (ja)	2005-04-27	2015-09-09	アリーナファーマシューティカルズ，インコーポレイテッド	肥満および糖尿病、ならびにそれらに関連する病態の処置のため、ならびに血中ｇｌｐ−１レベルを増大させることによって緩和される病態の処置のための、併用療法
EP1910290A2 (en) *	2005-06-30	2008-04-16	Prosidion Limited	Gpcr agonists
DE102005035891A1 (de)	2005-07-30	2007-02-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
WO2007056580A2 (en) *	2005-11-08	2007-05-18	Pharmadyn, Inc.	Methods and compositions for treating diseases associated with pathogenic proteins
PE20071221A1 (es) *	2006-04-11	2007-12-14	Arena Pharm Inc	Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
SG10201404220TA (en)	2006-04-11	2014-10-30	Arena Pharm Inc	Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
EP1852108A1 (en)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	DPP IV inhibitor formulations
PE20110235A1 (es)	2006-05-04	2011-04-14	Boehringer Ingelheim Int	Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
KR101452915B1 (ko)	2006-05-04	2014-10-21	베링거 인겔하임 인터내셔날 게엠베하	다형태
EP2043744A2 (en) *	2006-07-13	2009-04-08	SmithKline Beecham Corporation	Chemical compounds
US20080103123A1 (en) *	2006-08-30	2008-05-01	Biovitrum	New compounds
EP2112880A4 (en) *	2006-12-14	2011-12-21	Merck Sharp & Dohme	ACYLBIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND TREATMENT METHOD
US7638541B2 (en)	2006-12-28	2009-12-29	Metabolex Inc.	5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
US20100048632A1 (en) *	2007-01-04	2010-02-25	Matthew Colin Thor Fyfe	Piperidine GPCR Agonists
CL2008000018A1 (es) *	2007-01-04	2008-08-01	Prosidion Ltd	Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
PE20081849A1 (es) *	2007-01-04	2009-01-26	Prosidion Ltd	Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr
WO2008141074A1 (en) *	2007-05-10	2008-11-20	Salk Institute For Biological Studies	Identification of compounds that protect against amyloid diseases
AU2008279447A1 (en)	2007-07-19	2009-01-29	Metabolex, Inc.	N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
PE20090938A1 (es)	2007-08-16	2009-08-08	Boehringer Ingelheim Int	Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
RU2443699C2 (ru) *	2007-09-20	2012-02-27	Айрм Ллк	Соединения и композиции в качестве модуляторов активности gpr119
WO2009117421A2 (en) *	2008-03-17	2009-09-24	Kalypsys, Inc.	Heterocyclic modulators of gpr119 for treatment of disease
BRPI0909469A2 (pt) *	2008-03-31	2015-12-29	Metabolex Inc	compostos de oximetileno de arila e usos dos mesmos
PE20091730A1 (es)	2008-04-03	2009-12-10	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
EP2108960A1 (en)	2008-04-07	2009-10-14	Arena Pharmaceuticals, Inc.	Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
US20110065671A1 (en) *	2008-05-19	2011-03-17	Harris Joel M	Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
ATE557024T1 (de) *	2008-07-10	2012-05-15	Prosidion Ltd	Piperidinverbindungen als gpcr-agonisten
UY32030A (es)	2008-08-06	2010-03-26	Boehringer Ingelheim Int	"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20190016601A (ko)	2008-08-06	2019-02-18	베링거 인겔하임 인터내셔날 게엠베하	메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
CA2736421A1 (en)	2008-09-10	2010-03-18	Boehringer Ingelheim International Gmbh	Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR101054911B1 (ko)	2008-10-17	2011-08-05	동아제약주식회사	디펩티딜펩티다아제-ⅳ의 활성을 저해하는 화합물 및 다른 항당뇨 또는 항비만 약물을 유효성분으로 함유하는 당뇨 또는 비만의 예방 및 치료용 약학적 조성물
CN101723947B (zh) *	2008-10-21	2012-05-30	山东轩竹医药科技有限公司	二肽酶-ⅳ抑制剂化合物
JP2012512848A (ja)	2008-12-23	2012-06-07	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	有機化合物の塩の形態
WO2010074271A1 (ja) *	2008-12-26	2010-07-01	武田薬品工業株式会社	糖尿病治療剤
TW201036975A (en)	2009-01-07	2010-10-16	Boehringer Ingelheim Int	Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
US20220387305A1 (en) *	2009-01-12	2022-12-08	Biokier, Inc.	Composition and method for treatment of diabetes
BRPI1008560B1 (pt)	2009-02-13	2021-08-31	Boehringer Ingelheim International Gmbh	Composição farmacêutica compreendendo um inibidor de sglt2, um inibidor de dpp-iv e opcionalmente um outro agente antidiabético e usos dos mesmos
EP2414348B1 (en)	2009-04-03	2013-11-20	Merck Sharp & Dohme Corp.	Bicyclic piperidine and piperazine derivatives as gpcr modulators for the treatment of obesity, diabetes and other metabolic disorders
NZ596467A (en) *	2009-06-05	2014-01-31	Pfizer	L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators
EA201200046A1 (ru)	2009-06-24	2012-08-30	Бёрингер Ингельхайм Интернациональ Гмбх	Новые соединения, фармацевтическая композиция и связанные с ними способы
US8481731B2 (en)	2009-06-24	2013-07-09	Boehringer Ingelheim International Gmbh	Compounds, pharmaceutical composition and methods relating thereto
AR077642A1 (es)	2009-07-09	2011-09-14	Arena Pharm Inc	Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
SMT201700583T1 (it) *	2009-09-28	2018-01-11	Intarcia Therapeutics Inc	Instaurazione e/o terminazione rapida di erogazione di farmaci in modo sostanzialmente stazionario
US8410127B2 (en)	2009-10-01	2013-04-02	Metabolex, Inc.	Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
AU2010317842A1 (en)	2009-11-16	2012-07-12	Mellitech	[1,5]-diazocin derivatives
KR20240090632A (ko)	2009-11-27	2024-06-21	베링거 인겔하임 인터내셔날 게엠베하	리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
SG10201906876PA (en)	2010-01-27	2019-09-27	Arena Pharm Inc	Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
WO2011094632A1 (en) *	2010-01-29	2011-08-04	The Uab Research Foundation	Method for administration of insulin and pharmaceutical composition thereof
JP2013522279A (ja) *	2010-03-18	2013-06-13	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	糖尿病及び関連状態の治療で用いるｇｐｒ１１９作動薬とｄｄｐ−ｉｖ阻害薬リナグリプチンの組合せ
AU2011237775A1 (en)	2010-04-06	2012-11-22	Arena Pharmaceuticals, Inc.	Modulators of the GPR119 receptor and the treatment of disorders related thereto
CA3070513C (en)	2010-05-05	2023-01-03	Boehringer Ingelheim International Gmbh	A dpp-4 inhibitor for use in treatment of skin-alterations or necrosis
CN109674753A (zh)	2010-06-23	2019-04-26	希玛贝治疗股份有限公司	固态分散体
KR20130093012A (ko)	2010-06-24	2013-08-21	베링거 인겔하임 인터내셔날 게엠베하	당뇨병 요법
PH12013500547A1 (en)	2010-09-22	2013-06-10	Arena Pharm Inc	Modulators of the gpr119 receptor and the treatment of disorders related thereto
AR083878A1 (es)	2010-11-15	2013-03-27	Boehringer Ingelheim Int	Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
AR085689A1 (es)	2011-03-07	2013-10-23	Boehringer Ingelheim Int	Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
US20140018371A1 (en)	2011-04-01	2014-01-16	Arena Pharmaceuticals, Inc.	Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140066369A1 (en)	2011-04-19	2014-03-06	Arena Pharmaceuticals, Inc.	Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145604A1 (en)	2011-04-22	2012-10-26	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140038889A1 (en)	2011-04-22	2014-02-06	Arena Pharmaceuticals, Inc.	Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012170702A1 (en)	2011-06-08	2012-12-13	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
DK2731947T3 (da)	2011-07-15	2019-04-23	Boehringer Ingelheim Int	Substitueret dimerisk quinazolin-derivat, fremstilling og andvendelse deraf i farmaceutiske sammensætninger til behandling af type i- og type ii-diabetes
WO2013055910A1 (en)	2011-10-12	2013-04-18	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
WO2013171167A1 (en)	2012-05-14	2013-11-21	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013171166A1 (en)	2012-05-14	2013-11-21	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
CA2878625A1 (en)	2012-07-11	2014-01-16	Elcelyx Therapeutics, Inc.	Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
WO2014074668A1 (en)	2012-11-08	2014-05-15	Arena Pharmaceuticals, Inc.	Modulators of gpr119 and the treatment of disorders related thereto
CN103344773B (zh) *	2013-06-19	2015-04-15	天津美德太平洋科技有限公司	一种胰高血糖素样肽-1生物学活性检测试剂及检测方法和试剂盒
KR101688639B1 (ko)	2013-08-01	2016-12-21	경희대학교 산학협력단	당뇨병 예방 또는 치료용 약학적 조성물, 당뇨병 예방 또는 치료 방법, 및 당뇨병 치료제 스크리닝 방법
WO2015016682A1 (ko) *	2013-08-01	2015-02-05	경희대학교 산학협력단	당뇨병 예방 또는 치료용 약학적 조성물, 당뇨병 예방 또는 치료 방법, 및 당뇨병 치료제 스크리닝 방법
EP3110449B1 (en)	2014-02-28	2023-06-28	Boehringer Ingelheim International GmbH	Medical use of a dpp-4 inhibitor
MX386419B (es)	2015-01-06	2025-03-18	Arena Pharm Inc	Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
EA201791982A1 (ru)	2015-03-09	2020-02-17	Интекрин Терапьютикс, Инк.	Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
EP3939965A1 (en)	2015-06-22	2022-01-19	Arena Pharmaceuticals, Inc.	Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in sipi receptor-associated disorders
EP4233840A3 (en)	2016-06-10	2023-10-18	Boehringer Ingelheim International GmbH	Combinations of linagliptin and metformin
AU2017305392A1 (en)	2016-08-03	2019-02-21	Cymabay Therapeutics, Inc.	Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
MA47504A (fr)	2017-02-16	2019-12-25	Arena Pharm Inc	Composés et méthodes de traitement de l'angiocholite biliaire primitive
AU2018249822A1 (en)	2017-04-03	2019-10-31	Coherus Biosciences Inc.	PPArgamma agonist for treatment of progressive supranuclear palsy
US20200129511A1 (en)	2017-06-19	2020-04-30	Arena Pharmaceuticals, Inc.	Compounds and methods for treatment of nafld and nash
ES2987794T3 (es)	2018-06-06	2024-11-18	Arena Pharm Inc	Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1
KR102295300B1 (ko)	2018-09-12	2021-08-30	동아에스티 주식회사	Gpr119 리간드를 유효성분으로 포함하는 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물
BR112021026809A2 (pt)	2019-07-08	2022-02-22	Mankind Pharma Ltd	Terapia de combinação de agonistas de gpr119 e inibidores de dpp-4
WO2021182877A1 (ko) *	2020-03-11	2021-09-16	동아에스티 주식회사	당뇨 및 이에 동반하는 대사 질환의 예방 또는 치료를 위한 약학적 조성물
EP4227299A4 (en) *	2020-10-12	2025-04-09	Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd.	GLP-1 RECEPTOR AGONIST, BENZIMIDAZOLONE AND ITS USE
EP4615454A1 (en) *	2022-11-10	2025-09-17	Acerand Therapeutics (Hong Kong) Limited	Sos1 inhibitors

Family Cites Families (286)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US751426A (en) *		1904-02-02		Safety hair-pin
US747699A (en) *	1903-09-05	1903-12-22	Achilles C Gough	Universal sanding-machine.
US4166452A (en)	1976-05-03	1979-09-04	Generales Constantine D J Jr	Apparatus for testing human responses to stimuli
US4256108A (en)	1977-04-07	1981-03-17	Alza Corporation	Microporous-semipermeable laminated osmotic system
US4704362A (en)	1977-11-08	1987-11-03	Genentech, Inc.	Recombinant cloning vehicle microbial polypeptide expression
US4265874A (en)	1980-04-25	1981-05-05	Alza Corporation	Method of delivering drug with aid of effervescent activity generated in environment of use
DD296075A5 (de)	1989-08-07	1991-11-21	Martin-Luther-Universitaet Halle-Wittenberg,De	Verfahren zur herstellung neuer inhibitoren der dipeptidyl peptidase iv
EP0528858B1 (en)	1990-04-14	1997-01-22	New England Medical Center Hospitals, Inc.	Inhibitors of dipeptidyl-aminopeptidase type iv
US5462856A (en)	1990-07-19	1995-10-31	Bunsen Rush Laboratories, Inc.	Methods for identifying chemicals that act as agonists or antagonists for receptors and other proteins involved in signal transduction via pathways that utilize G-proteins
ES2153831T3 (es)	1991-10-22	2001-03-16	New England Medical Center Inc	Inhibidores de dipeptidil-aminopeptidasa de tipo iv.
MX9206628A (es)	1991-11-22	1993-05-01	Boehringer Ingelheim Pharma	Ester de prolinaboronato y metodo para su preparacion.
US6100042A (en)	1993-03-31	2000-08-08	Cadus Pharmaceutical Corporation	Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
IL111785A0 (en)	1993-12-03	1995-01-24	Ferring Bv	Dp-iv inhibitors and pharmaceutical compositions containing them
US5543396A (en)	1994-04-28	1996-08-06	Georgia Tech Research Corp.	Proline phosphonate derivatives
US20020006899A1 (en) *	1998-10-06	2002-01-17	Pospisilik Andrew J.	Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals
DE19616486C5 (de)	1996-04-25	2016-06-30	Royalty Pharma Collection Trust	Verfahren zur Senkung des Blutglukosespiegels in Säugern
WO1998018763A1 (en)	1996-10-25	1998-05-07	Tanabe Seiyaku Co., Ltd.	Tetrahydroisoquinoline derivatives
TW492957B (en)	1996-11-07	2002-07-01	Novartis Ag	N-substituted 2-cyanopyrrolidnes
US6100234A (en)	1997-05-07	2000-08-08	Tufts University	Treatment of HIV
US6040145A (en) *	1997-05-07	2000-03-21	Tufts University	Potentiation of the immune response
US6183974B1 (en) *	1997-07-31	2001-02-06	The General Hospital Corporation	Screening assays for G protein coupled receptor agonists and antagonists
CA2304206A1 (en)	1997-09-29	1999-04-08	Point Therapeutics, Inc.	Stimulation of hematopoietic cells in vitro
JP4095772B2 (ja)	1997-11-18	2008-06-04	財団法人微生物化学研究会	新規生理活性物質スルフォスチン、その製造法及びその用途
AU766219B2 (en)	1998-02-02	2003-10-09	1149336 Ontario Inc.	Method of regulating glucose metabolism, and reagents related thereto
US5922576A (en) *	1998-02-27	1999-07-13	The John Hopkins University	Simplified system for generating recombinant adenoviruses
CA2331122A1 (en)	1998-05-04	1999-11-11	Point Therapeutics, Inc.	Hematopoietic stimulation
DE19823831A1 (de) *	1998-05-28	1999-12-02	Probiodrug Ges Fuer Arzneim	Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
AU765370B2 (en)	1998-06-05	2003-09-18	Point Therapeutics, Inc.	Cyclic boroproline compounds
DE19828113A1 (de)	1998-06-24	2000-01-05	Probiodrug Ges Fuer Arzneim	Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19828114A1 (de) *	1998-06-24	2000-01-27	Probiodrug Ges Fuer Arzneim	Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19834591A1 (de)	1998-07-31	2000-02-03	Probiodrug Ges Fuer Arzneim	Verfahren zur Steigerung des Blutglukosespiegels in Säugern
EP1104293A1 (en)	1998-08-21	2001-06-06	Point Therapeutics, Inc.	Regulation of substrate activity
JP2002526554A (ja) *	1998-10-07	2002-08-20	メディカルカレッジオブジョージアリサーチインスティチュート，インコーポレイテッド	骨親和性ホルモンとして用いられるグルコース依存性インスリン親和性ペプチド
US6242422B1 (en)	1998-10-22	2001-06-05	Idun Pharmacueticals, Inc.	(Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
KR20080104062A (ko) *	1998-11-20	2008-11-28	아레나 파마슈티칼스, 인크.	사람의 오르판 ｇ 단백질 커플링 수용체
CO5150173A1 (es)	1998-12-10	2002-04-29	Novartis Ag	Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
JP2000191616A (ja)	1998-12-24	2000-07-11	Senju Pharmaceut Co Ltd	新規ジペプチジルアルデヒド誘導体およびそれを含有する医薬
US6221660B1 (en) *	1999-02-22	2001-04-24	Synaptic Pharmaceutical Corporation	DNA encoding SNORF25 receptor
US20030125539A1 (en) *	1999-02-22	2003-07-03	Synaptic Pharmaceutical Corporation	DNA encoding SNORF25 receptor
AU3960400A (en) *	1999-03-05	2000-09-28	Molteni L. E C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A.	Use of metformin in the preparation of pharmaceutical compositions capable of inhibiting the enzyme dipeptidyl peptidase iv
GB9906715D0 (en)	1999-03-23	1999-05-19	Ferring Bv	Compositions for promoting growth
GB9906714D0 (en)	1999-03-23	1999-05-19	Ferring Bv	Compositions for improving fertility
JP4121215B2 (ja)	1999-05-17	2008-07-23	財団法人微生物化学研究会	スルフォスチン類縁体、並びにスルフォスチン及びその類縁体の製造方法
EP1187619A1 (en)	1999-05-25	2002-03-20	Point Therapeutics, Inc.	Anti-tumor agents comprising boroproline compounds
US6617340B1 (en)	1999-07-29	2003-09-09	Novartis Ag	N-(substituted glycyl)-pyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
DE19940130A1 (de)	1999-08-24	2001-03-01	Probiodrug Ges Fuer Arzneim	Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung
US6653064B1 (en)	1999-09-23	2003-11-25	Boehringer Ingelheim International Gmbh	Method for identifying compounds useful in the therapy of bone disorders
GB9923177D0 (en)	1999-09-30	1999-12-01	Pfizer Ltd	Novel polypeptide
EP1228061A4 (en)	1999-11-12	2004-12-15	Guilford Pharm Inc	DIPEPTIDYL PEPTIDASE IV INHIBITORS; METHODS OF MANUFACTURE AND USE OF SAID INHIBITORS
US6380398B2 (en) *	2000-01-04	2002-04-30	Novo Nordisk A/S	Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV
PT1741446E (pt)	2000-01-21	2008-05-09	Novartis Pharma Ag	Combinações incluindo inibidores da dipeptidilpeptidase-iv e agentes anti-diabéticos
AU2001228309A1 (en)	2000-01-24	2001-08-07	Novo-Nordisk A/S	N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv
US6395767B2 (en)	2000-03-10	2002-05-28	Bristol-Myers Squibb Company	Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US6608038B2 (en) *	2000-03-15	2003-08-19	Novartis Ag	Methods and compositions for treatment of diabetes and related conditions via gene therapy
GB0010183D0 (en)	2000-04-26	2000-06-14	Ferring Bv	Inhibitors of dipeptidyl peptidase IV
GB0010188D0 (en)	2000-04-26	2000-06-14	Ferring Bv	Inhibitors of dipeptidyl peptidase IV
ATE348162T1 (de) *	2000-05-18	2007-01-15	Bayer Healthcare Ag	Regulation eines menschlichen dopamine-ähnlichen g-protein gekoppelten rezeptor.
TW583185B (en)	2000-06-13	2004-04-11	Novartis Ag	N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same
US6432969B1 (en)	2000-06-13	2002-08-13	Novartis Ag	N-(substituted glycyl)-2 cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US20030219825A1 (en) *	2000-06-13	2003-11-27	Haizlip Jill Elaine	High throughput method for screening candidate compounds for biological activity
GB0014969D0 (en)	2000-06-19	2000-08-09	Smithkline Beecham Plc	Novel method of treatment
WO2002002560A2 (en)	2000-07-04	2002-01-10	Novo Nordisk A/S	Purine-2,6-diones which are inhibitors of the enzyme dipeptidyl peptidase iv (dpp-iv)
WO2002008188A1 (en) *	2000-07-25	2002-01-31	Merck & Co., Inc.	N-substituted indoles useful in the treatment of diabetes
US7074794B2 (en)	2000-08-10	2006-07-11	Mitsubishi Pharma Corporation	Proline derivatives and the use thereof as drugs
JP2004035574A (ja)	2000-10-06	2004-02-05	Tanabe Seiyaku Co Ltd	脂肪族含窒素五員環化合物
JP4329290B2 (ja)	2000-10-06	2009-09-09	田辺三菱製薬株式会社	脂肪族含窒素五員環化合物
JP4329291B2 (ja)	2000-10-06	2009-09-09	田辺三菱製薬株式会社	含窒素五員環化合物
US7138397B2 (en)	2000-10-06	2006-11-21	Tanabe Seiyaku Co., Ltd.	Nitrogenous 5-membered ring compounds
AUPR107800A0 (en)	2000-10-27	2000-11-23	University Of Sydney, The	Peptide and nucleic acid molecule ii
TWI243162B (en)	2000-11-10	2005-11-11	Taisho Pharmaceutical Co Ltd	Cyanopyrrolidine derivatives
WO2002042461A2 (en)	2000-11-27	2002-05-30	Arena Pharmaceuticals, Inc.	Endogenous and non-endogenous versions of human g protein-coupled receptors
ES2280435T3 (es) *	2000-12-01	2007-09-16	Astellas Pharma Inc.	Metodo de exploracion de remedios para la diabetes.
WO2002051836A1 (en)	2000-12-27	2002-07-04	Kyowa Hakko Kogyo Co., Ltd.	Dipeptidyl peptidase iv inhibitor
WO2002055088A1 (en)	2001-01-16	2002-07-18	Nippon Kayaku Kabushiki Kaisha	Remedies for bone marrow suppression and infectious diseases and white blood cell count elevating agents
US6397767B1 (en) *	2001-02-01	2002-06-04	Case Corporation	Knife applicator for applying liquid fertilizer in the ground
JP4213390B2 (ja)	2001-02-02	2009-01-21	武田薬品工業株式会社	縮合複素環化合物
CN1500080A (zh)	2001-02-02	2004-05-26	��ҩƷ��ҵ��ʽ��	稠合杂环化合物
KR100926247B1 (ko)	2001-02-24	2009-11-12	베링거 잉겔하임 파르마 게엠베하 운트 코 카게	크산틴 유도체를 포함하는 약제학적 조성물 및 이의제조방법
JP2002265439A (ja)	2001-03-08	2002-09-18	Mitsubishi Pharma Corp	シアノピロリジン誘導体およびその医薬用途
AU2002338329B2 (en) *	2001-03-27	2006-09-07	The Regents Of The University Of California	Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism
ATE395912T1 (de)	2001-03-27	2008-06-15	Merck & Co Inc	Dipeptidylpeptidase-hemmer für die behandlung oder prävention von diabetes
FR2822826B1 (fr)	2001-03-28	2003-05-09	Servier Lab	Nouveaux derives sulfonyles d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB0109146D0 (en)	2001-04-11	2001-05-30	Ferring Bv	Treatment of type 2 diabetes
US6573287B2 (en)	2001-04-12	2003-06-03	Bristo-Myers Squibb Company	2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
FR2824825B1 (fr)	2001-05-15	2005-05-06	Servier Lab	Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ES2257555T3 (es)	2001-06-20	2006-08-01	MERCK & CO., INC.	Inhibidores de dipeptidilpeptidasa para el tratamiento de la diabetes.
EP1406872B1 (en)	2001-06-20	2007-12-19	Merck & Co., Inc.	Dipeptidyl peptidase inhibitors for the treatment of diabetes
GB0115517D0 (en)	2001-06-25	2001-08-15	Ferring Bv	Novel antidiabetic agents
US7368421B2 (en) *	2001-06-27	2008-05-06	Probiodrug Ag	Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
CA2418543A1 (en)	2001-06-27	2003-01-09	Probiodrug Ag	New dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents
US20030130199A1 (en) *	2001-06-27	2003-07-10	Von Hoersten Stephan	Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
ES2296979T3 (es)	2001-06-27	2008-05-01	Smithkline Beecham Corporation	Fluoropirrolidinas como inhibidores de dipeptidil peptidasa.
JP4300108B2 (ja)	2001-06-27	2009-07-22	スミスクラインビーチャムコーポレーション	ジペプチジルペプチダーゼ阻害剤としてのピロリジン類
DE60221983T2 (de)	2001-06-27	2008-05-15	Smithkline Beecham Corp.	Fluorpyrrolidine als dipeptidyl-peptidase inhibitoren
RU2299066C2 (ru)	2001-06-27	2007-05-20	Пробиодруг Аг	Новые ингибиторы дипептидилпептидазы iv и их применение в качестве противораковых агентов
DE10154689A1 (de)	2001-11-09	2003-05-22	Probiodrug Ag	Substituierte Aminoketonverbindungen
US6869947B2 (en) *	2001-07-03	2005-03-22	Novo Nordisk A/S	Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
WO2003004496A1 (en)	2001-07-03	2003-01-16	Novo Nordisk A/S	Dpp-iv-inhibiting purine derivatives for the treatment of diabetes
UA74912C2 (en)	2001-07-06	2006-02-15	Merck & Co Inc	Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US6844316B2 (en) *	2001-09-06	2005-01-18	Probiodrug Ag	Inhibitors of dipeptidyl peptidase I
DE10143840A1 (de)	2001-09-06	2003-03-27	Probiodrug Ag	Neue Inhibitoren der Dipeptidylpeptidase I
WO2003024942A1 (en)	2001-09-14	2003-03-27	Mitsubishi Pharma Corporation	Thiazolidine derivative and medicinal use thereof
WO2003026661A1 (fr) *	2001-09-14	2003-04-03	Yamanouchi Pharmaceutical Co., Ltd.	Accelerateur de secretion de l'insuline et nouveau derive de pyrimidine
EP1463727A2 (en)	2001-09-19	2004-10-06	Novo Nordisk A/S	Heterocyclic compounds that are inhibitors of the enzyme dpp-iv
US7238671B2 (en)	2001-10-18	2007-07-03	Bristol-Myers Squibb Company	Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
CA2463908A1 (en)	2001-10-18	2003-04-24	Bristol-Myers Squibb Company	Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
GB0125446D0 (en)	2001-10-23	2001-12-12	Ferring Bv	Novel anti-diabetic agents
GB0125445D0 (en)	2001-10-23	2001-12-12	Ferring Bv	Protease Inhibitors
US6861440B2 (en)	2001-10-26	2005-03-01	Hoffmann-La Roche Inc.	DPP IV inhibitors
CA2464995A1 (en)	2001-10-31	2003-05-08	Novartis Ag	Methods to treat diabetes and related conditions based on polymorphisms in the tcf1 gene
US20030125304A1 (en) *	2001-11-09	2003-07-03	Hans-Ulrich Demuth	Substituted amino ketone compounds
WO2003045228A2 (en)	2001-11-26	2003-06-05	Trustees Of Tufts College	Methods for treating autoimmune disorders, and reagents related thereto
EP1469873A4 (en)	2001-11-26	2007-10-03	Tufts College	PEPTIDOMIMETIC INHIBITORS FROM BEHIND PROLIN SPLENDING ENZYMES
AU2002360732A1 (en)	2001-12-26	2003-07-24	Guilford Pharmaceuticals	Change inhibitors of dipeptidyl peptidase iv
US6727261B2 (en) *	2001-12-27	2004-04-27	Hoffman-La Roche Inc.	Pyrido[2,1-A]Isoquinoline derivatives
CA2475653A1 (en)	2002-02-08	2003-09-04	Idun Pharmaceuticals, Inc.	(substituted)acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
ES2252656T3 (es)	2002-02-13	2006-05-16	F. Hoffmann-La Roche Ag	Nuevos derivados de piridina y quinolina.
KR100608414B1 (ko)	2002-02-13	2006-08-02	에프. 호프만-라 로슈 아게	신규한 피리딘- 및 피리미딘-유도체
US6906074B2 (en)	2002-02-22	2005-06-14	Nippon Zoki Pharmaceutical Co., Ltd.	2-phenylpiperazine derivatives
JP2004043429A (ja)	2002-02-25	2004-02-12	Eisai Co Ltd	新規キサンチン誘導体およびｄｐｐｉｖ阻害剤
DE60304911D1 (de) *	2002-02-25	2006-06-08	Eisai Co Ltd	Xanthin-Derivate als DPP-IV-Inhibitoren
JP2005527504A (ja)	2002-02-28	2005-09-15	プロシディオン・リミテッド	グルタミニルを基礎するｄｐｉｖ阻害剤
HUP0200849A2 (hu) *	2002-03-06	2004-08-30	Sanofi-Synthelabo	N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
WO2003080633A1 (fr)	2002-03-25	2003-10-02	Nippon Kayaku Kabushiki Kaisha	Nouveau derive d'$g(a)-amino-n-(diaminophosphinyl)lactame
ATE373660T1 (de)	2002-03-25	2007-10-15	Merck & Co Inc	Heterocyclische beta-aminoverbindungen als inhibitoren der dipeptidylpeptidase zur behandlung bzw. prävention von diabetes
JP4329382B2 (ja)	2002-04-04	2009-09-09	田辺三菱製薬株式会社	医薬組成物
JP4329381B2 (ja)	2002-04-04	2009-09-09	田辺三菱製薬株式会社	医薬組成物
BR0308816A (pt)	2002-04-08	2005-03-22	Torrent Pharmaceuticals Ltd	Tiazolidina-4-carbonitrilas e análogos e seus usos como inibidores da dipeptil-peptidas
JP2003300977A (ja)	2002-04-10	2003-10-21	Sumitomo Pharmaceut Co Ltd	キサンチン誘導体
AU2003235913A1 (en)	2002-05-09	2003-11-11	Taisho Pharmaceutical Co., Ltd.	Cyanopyrrolidine derivatives
JP2004026820A (ja)	2002-05-09	2004-01-29	Taisho Pharmaceut Co Ltd	ジペプチジルペプチダーゼｉｖ阻害剤
JP2003327532A (ja)	2002-05-10	2003-11-19	Takeda Chem Ind Ltd	ペプチダーゼ阻害剤
GB0212412D0 (en)	2002-05-29	2002-07-10	Novartis Ag	Combination of organic compounds
CN100402026C (zh)	2002-06-03	2008-07-16	诺瓦提斯公司	取代的氰基吡咯烷和含有它们的组合制剂用于治疗高脂血症和相关疾病的用途
WO2003101449A2 (en)	2002-06-04	2003-12-11	Pfizer Products Inc.	Process for the preparation of 3,3,4,4-tetrafluoropyrrolidine and derivatives thereof
US6710040B1 (en)	2002-06-04	2004-03-23	Pfizer Inc.	Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors
JP2005533771A (ja)	2002-06-04	2005-11-10	ファイザー・プロダクツ・インク	ジペプチジルペプチダーゼｉｖ阻害剤としてのフッ素化環式アミド
MXPA04012226A (es)	2002-06-06	2005-04-08	Eisai Co Ltd	Nuevos derivados de imidazola.
HUP0202001A2 (hu)	2002-06-14	2005-08-29	Sanofi-Aventis	DDP-IV gátló hatású azabiciklooktán- és nonánszármazékok
JP2004026678A (ja)	2002-06-24	2004-01-29	Microbial Chem Res Found	２型糖尿病治療剤
US20050084490A1 (en)	2002-07-09	2005-04-21	Point Therapeutics, Inc.	Boroproline compound combination therapy
WO2004007446A1 (ja)	2002-07-10	2004-01-22	Yamanouchi Pharmaceutical Co., Ltd.	新規なアゼチジン誘導体又はその塩
US7208498B2 (en) *	2002-07-15	2007-04-24	Merck & Co., Inc.	Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes
TW200401635A (en)	2002-07-23	2004-02-01	Yamanouchi Pharma Co Ltd	2-Cyano-4-fluoropyrrolidine derivative or salt thereof
AU2003254852A1 (en)	2002-08-08	2004-02-25	Takeda Pharmaceutical Company Limited	Fused heterocyclic compounds as peptidase inhibitors
JP4542757B2 (ja)	2002-08-08	2010-09-15	武田薬品工業株式会社	縮合複素環化合物
DE10236667B4 (de) *	2002-08-09	2007-06-06	J. Eberspächer GmbH & Co. KG	Abgasanlage für den Verbrennungsmotor eines Kraftfahrzeugs
AU2003296895A1 (en) *	2002-08-20	2004-05-04	The Regents Of The University Of California	Combination therapy for controlling appetites
EP1532149B9 (de)	2002-08-21	2011-04-20	Boehringer Ingelheim Pharma GmbH & Co. KG	8-[3-amino-piperidin-1-yl] -xanthine, deren herstellung und deren verwendung als arzneimittel
US7407955B2 (en) *	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE10238243A1 (de)	2002-08-21	2004-03-04	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE10238477A1 (de)	2002-08-22	2004-03-04	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Purinderivate, deren Herstellung und deren Verwendung als Arzneimittel
DE10238470A1 (de)	2002-08-22	2004-03-04	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
ZA200501418B (en)	2002-08-29	2006-10-25	Taisho Pharmaceutical Co Ltd	Benzenesulfonate salts of 4-fluoro-2-cyanopyrrolidine derivatives
WO2004024184A1 (ja) *	2002-09-11	2004-03-25	Takeda Pharmaceutical Company Limited	徐放性製剤
AU2003262042A1 (en) *	2002-09-11	2004-04-30	Yamanouchi Pharmaceutical Co., Ltd.	Method of screening insulin content enhancer
ATE370141T1 (de)	2002-10-07	2007-09-15	Merck & Co Inc	Antidiabetische heterocyclische beta- aminoverbindungen als inhibitoren von dipeptidylpeptidase
AU2003269850A1 (en)	2002-10-08	2004-05-04	Novo Nordisk A/S	Hemisuccinate salts of heterocyclic dpp-iv inhibitors
AR041470A1 (es) *	2002-10-17	2005-05-18	Upjohn Co	Compuestos de pirrolo (1,2 - b) piridazina y sus usos
KR20050067418A (ko)	2002-10-18	2005-07-01	머크 앤드 캄파니 인코포레이티드	당뇨병을 치료 또는 예방하기 위한 베타-아미노헤테로사이클릭 디펩티딜 펩티다제 억제제
DE60332856D1 (de)	2002-10-23	2010-07-15	Bristol Myers Squibb Co	Auf glycinnitril basierende hemmer der dipeptidylpeptidase iv
WO2004041795A1 (en)	2002-10-30	2004-05-21	Guilford Pharmaceuticals Inc.	Novel inhibitors of dipeptidyl peptidase iv
AU2003280680A1 (en)	2002-11-01	2004-06-18	Sumitomo Pharmaceuticals Co., Ltd.	Xanthine compound
EP1562925B1 (en)	2002-11-07	2007-01-03	Merck & Co., Inc.	Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US7482337B2 (en) *	2002-11-08	2009-01-27	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10251927A1 (de)	2002-11-08	2004-05-19	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
EP1565437A1 (en) *	2002-11-18	2005-08-24	Pfizer Products Inc.	Dipeptidyl peptidase iv inhibiting fluorinated cyclic amides
UY28103A1 (es)	2002-12-03	2004-06-30	Boehringer Ingelheim Pharma	Nuevas imidazo-piridinonas sustituidas, su preparación y su empleo como medicacmentos
DE10256264A1 (de)	2002-12-03	2004-06-24	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue substituierte Imidazo-pyridinone und Imidazo-pyridazinone, ihre Herstellung und ihre Verwendung als Arzneimittel
AU2003297564A1 (en)	2002-12-04	2004-06-23	Merck & Co., Inc.	Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US7420079B2 (en)	2002-12-09	2008-09-02	Bristol-Myers Squibb Company	Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof
ES2311117T3 (es)	2002-12-10	2009-02-01	Novartis Ag	Combinacion de un inhibidor de dpp-iv y un compuesto ppar-alfa.
WO2004058266A1 (en)	2002-12-20	2004-07-15	Merck & Co., Inc.	3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US6982164B2 (en) *	2003-01-10	2006-01-03	Mgp Ingredients, Inc.	Unhydrolyzed jojoba protein products having high simmondsin concentration
MXPA05007485A (es) *	2003-01-14	2006-01-30	Arena Pharm Inc	Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
WO2004064778A2 (en)	2003-01-17	2004-08-05	Merck & Co. Inc.	3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
JP2004244412A (ja)	2003-01-20	2004-09-02	Kotobuki Seiyaku Kk	４位に置換基を有する２−シアノピロリジン誘導体及びその製造方法並びにそれを含有する薬剤
PT1595866T (pt)	2003-01-31	2016-09-14	Sanwa Kagaku Kenkyusho Co	Cianopirrolidinas úteis para o tratamento entre outras de síndrome metabólica
WO2004069162A2 (en)	2003-01-31	2004-08-19	Merck & Co., Inc.	3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2004071454A2 (en)	2003-02-13	2004-08-26	Guilford Pharmaceuticals Inc.	Substituted azetidine compounds as inhibitors of dipeptidyl peptidase iv
ES2316964T3 (es) *	2003-02-24	2009-04-16	Arena Pharmaceuticals, Inc.	Fenil-y piridilpipereidinia-derivados como moduladores del metabolismo de la glucosa.
WO2004076434A1 (en)	2003-02-28	2004-09-10	Aic	Dipeptidyl peptidase inhibitors
AU2003207881A1 (en)	2003-02-28	2004-09-17	Aic	Dipeptidyl peptidase inhibitors
JP2004269468A (ja) *	2003-03-12	2004-09-30	Yamanouchi Pharmaceut Co Ltd	ピリミジン誘導体又はその塩
JP2004269469A (ja) *	2003-03-12	2004-09-30	Yamanouchi Pharmaceut Co Ltd	ピリミジン誘導体又はその塩
AR043515A1 (es)	2003-03-19	2005-08-03	Merck & Co Inc	Procedimiento para preparar derivados quirales beta aminoacidos mediante hidrogenacion asimetrica
WO2004085661A2 (en)	2003-03-24	2004-10-07	Merck & Co., Inc	Process to chiral beta-amino acid derivatives
US7550590B2 (en)	2003-03-25	2009-06-23	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
WO2004087650A2 (en)	2003-03-27	2004-10-14	Merck & Co. Inc.	Process and intermediates for the preparation of beta-amino acid amide dipeptidyl peptidase-iv inhibitors
WO2004092128A1 (en)	2003-04-10	2004-10-28	Smithkline Beecham Corporation	Anhydrous crystalline forms of (2s, 4s)-1-{(2r)-2-amino-3-‘4-methoxybenzyl)sulfonyl!-3-methylbutanoyl}-4-fluoropyrrolindine-2-carbonitrile
WO2004096806A1 (ja)	2003-04-30	2004-11-11	Sumitomo Pharmaceuticals Co. Ltd.	縮合イミダゾール誘導体
US20040229848A1 (en)	2003-05-05	2004-11-18	Hans-Ulrich Demuth	Glutaminyl based DP IV-inhibitors
JP4806628B2 (ja) *	2003-05-05	2011-11-02	プロビオドルグエージー	グルタミニルシクラーゼ阻害剤
US7083933B1 (en)	2003-05-09	2006-08-01	Prosidion Limited	Methods for identification of modulators of OSGPR116 activity
WO2004103276A2 (en)	2003-05-14	2004-12-02	Merck & Co., Inc.	3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2004103993A1 (en)	2003-05-14	2004-12-02	Syrrx, Inc.	Dipeptidyl peptidase inhibitors
EP1627870A1 (en)	2003-05-15	2006-02-22	Taisho Pharmaceutical Co., Ltd	Cyanofluoropyrrolidine derivative
EP1631680A2 (en)	2003-05-21	2006-03-08	Bayer HealthCare AG	Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase iv (dpp4)
WO2004104215A2 (en)	2003-05-21	2004-12-02	Bayer Healthcare Ag	Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase 7 (dpp7)
AU2003902828A0 (en)	2003-06-05	2003-06-26	Fujisawa Pharmaceutical Co., Ltd.	Dpp-iv inhibitor
WO2004110436A1 (en)	2003-06-06	2004-12-23	Merck & Co., Inc.	Fused indoles as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
EP1635832A2 (en)	2003-06-06	2006-03-22	Merck & Co., Inc.	Combination therapy for the treatment of diabetes
AU2003902946A0 (en)	2003-06-12	2003-06-26	Fujisawa Pharmaceutical Co., Ltd.	Dpp-iv inhibitor
CN1809544A (zh)	2003-06-17	2006-07-26	麦克公司	作为二肽基肽酶抑制剂用于治疗或预防糖尿病的环己基甘氨酸衍生物
DE10327439A1 (de)	2003-06-18	2005-01-05	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Imidazopyridazinon- und Imidazopyridonderivate, deren Herstellung und deren Verwendung als Arzneimittel
RU2339636C2 (ru)	2003-06-20	2008-11-27	Ф.Хоффманн-Ля Рош Аг	Гексагидропиридоизохинолины в качестве ингибиторов дипептидилпептидазы iv (dpp-iv)
ES2355105T3 (es)	2003-06-20	2011-03-22	F. Hoffmann-La Roche Ag	Pirido(2,1-a)isoquinolina como inhibidores de la dpp-iv.
JO2625B1 (en) *	2003-06-24	2011-11-01	ميرك شارب اند دوم كوربوريشن	Phosphoric acid salts of dipeptidyl betidase inhibitor 4
JP2005023038A (ja)	2003-07-04	2005-01-27	Taisho Pharmaceut Co Ltd	慢性腎疾患治療薬
AR045047A1 (es) *	2003-07-11	2005-10-12	Arena Pharm Inc	Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
US7132426B2 (en)	2003-07-14	2006-11-07	Arena Pharmaceuticals, Inc.	Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
AU2004259741A1 (en)	2003-07-21	2005-02-03	Smithkline Beecham Corporation	(2S,4S)-4-fluoro-1-[4-fluoro-beta-(4-fluorophenyl)-L-phenylalanyl]-2-pyrrolidinecarbonitrile p-toluenesulfonic acid salt and anhydrous crystalline forms thereof
PE20050249A1 (es)	2003-07-25	2005-06-01	Aventis Pharma Gmbh	Nuevas cianopirrolididas y procedimiento para su preparacion como medicamentos
DE10333935A1 (de)	2003-07-25	2005-02-24	Aventis Pharma Deutschland Gmbh	Neue bicyclische Cyanoheterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7094800B2 (en) *	2003-07-25	2006-08-22	Sanofi-Aventis Deutschland Gmbh	Cyanopyrrolidides, process for their preparation and their use as medicaments
US7008957B2 (en) *	2003-07-25	2006-03-07	Sanofi-Aventis Deutschland Gmbh	Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments
AU2004261186A1 (en)	2003-07-31	2005-02-10	Merck & Co., Inc.	Hexahydrodiazepinones as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
US6995183B2 (en)	2003-08-01	2006-02-07	Bristol Myers Squibb Company	Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
WO2005019168A2 (en) *	2003-08-20	2005-03-03	Pfizer Products Inc.	Fluorinated lysine derivatives as dipeptidyl peptidase iv inhibitors
HU227684B1 (en)	2003-08-29	2011-11-28	Sanofi Aventis	Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors
EP1659123A1 (en)	2003-08-29	2006-05-24	Dainippon Sumitomo Pharma Co., Ltd.	Bicyclic pyrazole derivative
CA2536251C (en)	2003-09-02	2009-08-04	Merck & Co., Inc.	Novel crystalline forms of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
WO2005023762A1 (en)	2003-09-04	2005-03-17	Abbott Laboratories	Pyrrolidine-2-carbonitrile derivatives and their use as inhibitors of dipeptidyl peptidase-iv (dpp-iv)
WO2005030751A2 (en)	2003-09-08	2005-04-07	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US7790734B2 (en)	2003-09-08	2010-09-07	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
AR046330A1 (es)	2003-09-09	2005-12-07	Japan Tobacco Inc	Inhibidor de dipeptidilpeptidasa iv
WO2005030127A2 (en)	2003-09-23	2005-04-07	Merck & Co., Inc.	Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
US20070072810A1 (en)	2003-10-03	2007-03-29	Takeda Pharmaceutical Company, Limited	Agent for treating diabetes
WO2005033099A2 (en)	2003-10-03	2005-04-14	Glenmark Pharmaceuticals Ltd.	Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof
DE10348044A1 (de)	2003-10-15	2005-05-19	Imtm Gmbh	Duale Alanyl-Aminopeptidase- und Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
DE10348022A1 (de)	2003-10-15	2005-05-25	Imtm Gmbh	Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
GB0324236D0 (en)	2003-10-16	2003-11-19	Astrazeneca Ab	Chemical compounds
TW200519105A (en)	2003-10-20	2005-06-16	Lg Life Science Ltd	Novel inhibitors of DPP-IV, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent
TW200523252A (en)	2003-10-31	2005-07-16	Takeda Pharmaceutical	Pyridine compounds
JP2007510651A (ja)	2003-11-04	2007-04-26	メルク　エンド　カムパニー　インコーポレーテッド	糖尿病の治療又は予防のためのジペプチジルペプチダーゼ−ｉｖ阻害剤としての縮合フェニルアラニン誘導体
NZ547752A (en)	2003-11-12	2009-12-24	Phenomix Corp	Heterocyclic boronic acid compounds for inhibiting dipeptidyl peptidase-IV
KR20120008093A (ko)	2003-11-17	2012-01-25	노파르티스 아게	디펩티딜 펩티다제 ⅳ 억제제의 용도
DE10355304A1 (de) *	2003-11-27	2005-06-23	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
WO2005058849A1 (en)	2003-12-15	2005-06-30	Glenmark Pharmaceuticals Ltd.	New dipeptidyl peptidase in inhibitors; process for their preparation and compositions containing them
US7217711B2 (en) *	2003-12-17	2007-05-15	Boehringer Ingelheim International Gmbh	Piperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutical compositions
DE10360835A1 (de)	2003-12-23	2005-07-21	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel
JP4958560B2 (ja)	2003-12-24	2012-06-20	プロシディオン・リミテッド	Ｇｐｃｒ受容体作動薬としてのヘテロ環誘導体
WO2005072530A1 (en)	2004-01-16	2005-08-11	Merck & Co., Inc.	Novel crystalline salts of a dipeptidyl peptidase-iv inhibitor
WO2005075426A1 (en)	2004-02-03	2005-08-18	Glenmark Pharmaceuticals Ltd.	Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof
US7501426B2 (en) *	2004-02-18	2009-03-10	Boehringer Ingelheim International Gmbh	8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
AU2005215136A1 (en)	2004-02-20	2005-09-01	Novartis Ag	DPP-IV inhibitors for treating neurodegeneration and cognitive disorders
DE102004009039A1 (de) *	2004-02-23	2005-09-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
CN101090885A (zh)	2004-02-23	2007-12-19	塔夫茨大学信托人	作为构象限定的肽模拟物抑制剂的内酰胺类化合物
US20050203027A1 (en)	2004-02-23	2005-09-15	Trustees Of Tufts College	Inhibitors of dipeptidylpeptidase IV
EP1729774A4 (en)	2004-03-09	2009-05-06	Nat Health Research Institutes	PYRROLIDINE CONNECTIONS
EA011671B1 (ru) *	2004-06-04	2009-04-28	Арена Фармасьютикалз, Инк.	Замещенные производные арила и гетероарила в качестве модуляторов метаболизма и для профилактики и лечения связанных с ним расстройств
US20060024313A1 (en) *	2004-07-06	2006-02-02	Xin Chen	Agents that disrupt dimer formation in DPP-IV family of prolyl dipeptidases
WO2006019965A2 (en) *	2004-07-16	2006-02-23	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
DE102004037554A1 (de)	2004-08-03	2006-03-16	Sanofi-Aventis Deutschland Gmbh	Substituierte 8-Aminoalkylthio-xanthine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004038268A1 (de)	2004-08-06	2006-03-16	Sanofi-Aventis Deutschland Gmbh	Substituierte, bizyklische 8-Pyrrolidino-xanthine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20060046978A1 (en) *	2004-08-31	2006-03-02	Morphochem Ag	Novel compounds that inhibit dipeptidyl peptidase (DPP-IV) and neprilysin (NEP) and/or angiotensin converting enzyme (ACE)
DE102004043944A1 (de)	2004-09-11	2006-03-30	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004044221A1 (de) *	2004-09-14	2006-03-16	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
CA2582588A1 (en) *	2004-10-07	2006-04-20	Merck & Co., Inc.	Acyclic hydrazides as cannabinoid receptor modulators
US20090253752A1 (en) *	2004-10-25	2009-10-08	Bryan Burkey	Combination of dpp-iv inhibitor, ppar antidiabetic and metmorfin
US7411093B2 (en) *	2004-12-20	2008-08-12	Hoffman-La Roche Inc.	Aminocycloalkanes as DPP-IV inhibitors
WO2006068978A2 (en) *	2004-12-21	2006-06-29	Takeda Pharmaceutial Company Limited	Dipeptidyl peptidase inhibitors
US20080318922A1 (en)	2004-12-24	2008-12-25	Dainippon Sumitomo Pharma Co., Ltd.	Bicyclic Pyrrole Derivatives
US7589088B2 (en) *	2004-12-29	2009-09-15	Bristol-Myers Squibb Company	Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
MY148521A (en) *	2005-01-10	2013-04-30	Arena Pharm Inc	Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
DOP2006000008A (es) *	2005-01-10	2006-08-31	Arena Pharm Inc	Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
US20070032420A1 (en) *	2005-02-09	2007-02-08	Entelos, Inc.	Treating diabetes with glucagon-like peptide-1 secretagogues
JP5774264B2 (ja) *	2005-04-27	2015-09-09	アリーナファーマシューティカルズ，インコーポレイテッド	肥満および糖尿病、ならびにそれらに関連する病態の処置のため、ならびに血中ｇｌｐ−１レベルを増大させることによって緩和される病態の処置のための、併用療法
EP1902730A4 (en)	2005-06-09	2009-11-11	Banyu Pharma Co Ltd	NPY-Y2 AGONIST FOR USE AS A REMEDY FOR DIARRHOUSIC DISEASES
BRPI0612599A2 (pt) *	2005-06-30	2010-11-23	Prosidion Ltd	composto, composição farmacêutica compreendendo o mesmo, método de tratamento e uso do mesmo
WO2007003960A1 (en) *	2005-06-30	2007-01-11	Prosidion Limited	Gpcr agonists
WO2007003961A2 (en) *	2005-06-30	2007-01-11	Prosidion Limited	Gpcr agonists
US7708191B2 (en) *	2005-07-28	2010-05-04	Edwin Vega	Telebanking apparatus for transferring money or cash value between two parties in the same country or across national borders, for paying bills and browsing the internet
JP4827483B2 (ja) *	2005-10-04	2011-11-30	キヤノン株式会社	核酸試料処理装置
PE20071221A1 (es) *	2006-04-11	2007-12-14	Arena Pharm Inc	Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
SG10201404220TA (en) *	2006-04-11	2014-10-30	Arena Pharm Inc	Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
EP2043744A2 (en) *	2006-07-13	2009-04-08	SmithKline Beecham Corporation	Chemical compounds
US20080103123A1 (en) *	2006-08-30	2008-05-01	Biovitrum	New compounds
ATE528300T1 (de) *	2006-12-06	2011-10-15	Glaxosmithkline Llc	Bizyklische verbindungen und ihre verwendung als antidiabetika
EP2112880A4 (en) *	2006-12-14	2011-12-21	Merck Sharp & Dohme	ACYLBIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND TREATMENT METHOD
BRPI0909469A2 (pt) *	2008-03-31	2015-12-29	Metabolex Inc	compostos de oximetileno de arila e usos dos mesmos
EP2108960A1 (en) *	2008-04-07	2009-10-14	Arena Pharmaceuticals, Inc.	Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
WO2009150144A1 (en) *	2008-06-10	2009-12-17	Inovacia Ab	New gpr119modulators
CA2736421A1 (en) *	2008-09-10	2010-03-18	Boehringer Ingelheim International Gmbh	Combination therapy for the treatment of diabetes and related conditions
WO2010074271A1 (ja) *	2008-12-26	2010-07-01	武田薬品工業株式会社	糖尿病治療剤
US20140193463A1 (en) *	2013-01-04	2014-07-10	China Medical University	Peptide for inhibiting dipeptidyl-peptidase iv

2006
- 2006-01-05 DO DO2006000008A patent/DOP2006000008A/es unknown
- 2006-01-06 PE PE2006000045A patent/PE20061116A1/es not_active Application Discontinuation
- 2006-01-06 GT GT200600004A patent/GT200600004A/es unknown
- 2006-01-06 PE PE2010000178A patent/PE20100398A1/es not_active Application Discontinuation
- 2006-01-09 HN HN2006000971A patent/HN2006000971A/es unknown
- 2006-01-09 EP EP07004743A patent/EP1808168B1/en not_active Revoked
- 2006-01-09 ES ES06717678T patent/ES2327268T5/es not_active Expired - Lifetime
- 2006-01-09 EP EP10010818A patent/EP2322150A3/en not_active Withdrawn
- 2006-01-09 SI SI200630363T patent/SI1808168T1/sl unknown
- 2006-01-09 PT PT07004743T patent/PT1808168E/pt unknown
- 2006-01-09 BR BRPI0606727-1A patent/BRPI0606727A/pt not_active IP Right Cessation
- 2006-01-09 US US11/328,405 patent/US20060154866A1/en not_active Abandoned
- 2006-01-09 AT AT06717678T patent/ATE431139T1/de active
- 2006-01-09 RS RSP-2009/0354A patent/RS51127B/sr unknown
- 2006-01-09 KR KR1020107010978A patent/KR101016890B1/ko not_active Expired - Fee Related
- 2006-01-09 CN CN2011100978256A patent/CN102218141A/zh active Pending
- 2006-01-09 EP EP10010819A patent/EP2322151A3/en not_active Withdrawn
- 2006-01-09 KR KR1020127029863A patent/KR20120139849A/ko not_active Withdrawn
- 2006-01-09 DE DE602006006765T patent/DE602006006765D1/de not_active Expired - Lifetime
- 2006-01-09 EP EP06717678A patent/EP1758565B2/en not_active Expired - Lifetime
- 2006-01-09 EP EP09006268A patent/EP2116235A1/en not_active Withdrawn
- 2006-01-09 SG SG201000208-7A patent/SG158876A1/en unknown
- 2006-01-09 DK DK07004743T patent/DK1808168T3/da active
- 2006-01-09 CA CA2593427A patent/CA2593427C/en not_active Expired - Fee Related
- 2006-01-09 NZ NZ578504A patent/NZ578504A/en not_active IP Right Cessation
- 2006-01-09 NZ NZ578502A patent/NZ578502A/en not_active IP Right Cessation
- 2006-01-09 CN CN201310606771.0A patent/CN103611161A/zh active Pending
- 2006-01-09 EP EP08009893A patent/EP1997484A3/en not_active Withdrawn
- 2006-01-09 PL PL06717678T patent/PL1758565T5/pl unknown
- 2006-01-09 SG SG2013026273A patent/SG189762A1/en unknown
- 2006-01-09 AT AT07004743T patent/ATE432693T1/de active
- 2006-01-09 NZ NZ556219A patent/NZ556219A/en not_active IP Right Cessation
- 2006-01-09 TW TW095100807A patent/TW200637534A/zh unknown
- 2006-01-09 EP EP10010820A patent/EP2322152A1/en not_active Withdrawn
- 2006-01-09 PT PT06717678T patent/PT1758565E/pt unknown
- 2006-01-09 EA EA200701469A patent/EA011883B1/ru not_active IP Right Cessation
- 2006-01-09 DE DE602006007093T patent/DE602006007093D1/de not_active Expired - Lifetime
- 2006-01-09 JP JP2007550512A patent/JP4118323B1/ja not_active Expired - Fee Related
- 2006-01-09 EP EP10010656A patent/EP2322156A1/en not_active Withdrawn
- 2006-01-09 SI SI200630362T patent/SI1758565T1/sl unknown
- 2006-01-09 EP EP10010659A patent/EP2322157A1/en not_active Withdrawn
- 2006-01-09 AR ARP060100072A patent/AR052082A1/es unknown
- 2006-01-09 PL PL07004743T patent/PL1808168T3/pl unknown
- 2006-01-09 ES ES07004743T patent/ES2327872T3/es not_active Expired - Lifetime
- 2006-01-09 NZ NZ587368A patent/NZ587368A/en not_active IP Right Cessation
- 2006-01-09 DK DK06717678.4T patent/DK1758565T4/da active
- 2006-01-09 KR KR1020077018318A patent/KR20070095400A/ko not_active Ceased
- 2006-01-09 HR HRP20090403TT patent/HRP20090403T4/hr unknown
- 2006-01-09 AU AU2006205164A patent/AU2006205164B2/en not_active Ceased
- 2006-01-09 MX MX2007008376A patent/MX2007008376A/es active IP Right Grant
- 2006-01-09 RS RSP-2009/0366A patent/RS51174B/sr unknown
- 2006-01-09 WO PCT/US2006/000510 patent/WO2006076231A2/en not_active Ceased
- 2006-01-09 CA CA2654733A patent/CA2654733C/en not_active Expired - Fee Related
- 2006-01-09 KR KR1020107023765A patent/KR20100129328A/ko not_active Ceased
- 2006-01-09 KR KR1020137032119A patent/KR20130140226A/ko not_active Ceased
- 2006-01-10 PA PA20068659301A patent/PA8659301A1/es unknown
- 2006-11-22 US US11/603,410 patent/US7803753B2/en not_active Expired - Fee Related
- 2006-11-22 US US11/603,417 patent/US7803754B2/en not_active Expired - Fee Related
2007
- 2007-07-02 IL IL184364A patent/IL184364A0/en unknown
- 2007-07-02 CR CR9220A patent/CR9220A/es not_active Application Discontinuation
- 2007-07-09 NI NI200700174A patent/NI200700174A/es unknown
- 2007-07-20 NO NO20073816A patent/NO331089B1/no not_active IP Right Cessation
- 2007-09-06 JP JP2007232094A patent/JP4787804B2/ja not_active Expired - Fee Related
2008
- 2008-03-17 JP JP2008068598A patent/JP4237243B2/ja not_active Expired - Fee Related
- 2008-03-17 JP JP2008068596A patent/JP4807887B2/ja not_active Expired - Fee Related
- 2008-03-17 JP JP2008068597A patent/JP4221444B2/ja not_active Expired - Fee Related
- 2008-04-16 JP JP2008107320A patent/JP4912349B2/ja not_active Expired - Fee Related
2009
- 2009-07-17 AU AU2009202898A patent/AU2009202898B2/en not_active Ceased
- 2009-07-17 AU AU2009202900A patent/AU2009202900B8/en not_active Ceased
- 2009-08-03 CY CY20091100816T patent/CY1109260T1/el unknown
- 2009-08-19 CY CY20091100881T patent/CY1109321T1/el unknown
- 2009-08-20 HR HR20090446T patent/HRP20090446T1/hr unknown
- 2009-10-30 US US12/609,599 patent/US20100137293A1/en not_active Abandoned
- 2009-11-02 US US12/610,918 patent/US20100286153A1/en not_active Abandoned
- 2009-11-02 US US12/610,682 patent/US8003597B2/en not_active Expired - Fee Related
- 2009-11-02 US US12/610,490 patent/US20100285494A1/en not_active Abandoned
- 2009-11-02 US US12/610,877 patent/US8022034B2/en not_active Expired - Fee Related
- 2009-11-02 US US12/610,674 patent/US8030270B2/en not_active Expired - Fee Related
- 2009-11-02 US US12/610,639 patent/US8198232B2/en not_active Expired - Fee Related
- 2009-11-02 US US12/610,885 patent/US20100286168A1/en not_active Abandoned
- 2009-11-02 US US12/610,967 patent/US20100298333A1/en not_active Abandoned
2010
- 2010-05-31 CL CL2010000565A patent/CL2010000565A1/es unknown
- 2010-12-09 NO NO20101746A patent/NO20101746L/no not_active Application Discontinuation
2011
- 2011-02-01 DO DO2011000040A patent/DOP2011000040A/es unknown
- 2011-06-07 JP JP2011127707A patent/JP2011184458A/ja not_active Withdrawn
- 2011-08-05 JP JP2011172381A patent/JP2012017330A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
ES2327268T3 (es)	2009-10-27
BRPI0606727A (pt)	2008-03-11
EP1758565B1 (en)	2009-05-13
JP4807887B2 (ja)	2011-11-02
JP2008239623A (ja)	2008-10-09
CA2654733A1 (en)	2006-07-20
AU2009202900B8 (en)	2010-06-03
CA2654733C (en)	2011-09-06
HRP20090446T1 (hr)	2009-09-30
US20100286153A1 (en)	2010-11-11
JP2008220375A (ja)	2008-09-25
CL2010000565A1 (es)	2010-10-15
EP2116235A1 (en)	2009-11-11
PL1808168T3 (pl)	2009-11-30
PL1758565T3 (pl)	2009-10-30
KR20100072085A (ko)	2010-06-29
RS51174B (sr)	2010-10-31
NZ578502A (en)	2011-01-28
JP2008195733A (ja)	2008-08-28
EP1997484A3 (en)	2009-02-11
EP1808168A1 (en)	2007-07-18
EA011883B1 (ru)	2009-06-30
US8030270B2 (en)	2011-10-04
PA8659301A1 (es)	2008-12-18
AU2006205164A1 (en)	2006-07-20
ES2327268T5 (es)	2013-03-21
US20070072803A1 (en)	2007-03-29
HK1096537A1 (en)	2007-06-01
AU2009202898B2 (en)	2010-02-18
JP4237243B2 (ja)	2009-03-11
EP2322150A3 (en)	2011-11-16
IL184364A0 (en)	2007-10-31
EP1758565A2 (en)	2007-03-07
CR9220A (es)	2009-07-31
SG158876A1 (en)	2010-02-26
US20100286111A1 (en)	2010-11-11
PE20100398A1 (es)	2010-06-07
NO20073816L (no)	2007-09-27
AU2009202900B2 (en)	2010-02-11
EP2322150A2 (en)	2011-05-18
WO2006076231A2 (en)	2006-07-20
HRP20090403T1 (hr)	2009-08-31
EP1758565B2 (en)	2012-11-14
CN103611161A (zh)	2014-03-05
US20100285494A1 (en)	2010-11-11
EP1808168B1 (en)	2009-06-03
DOP2011000040A (es)	2011-09-30
CY1109321T1 (el)	2014-07-02
KR20130140226A (ko)	2013-12-23
KR20120139849A (ko)	2012-12-27
ES2327872T3 (es)	2009-11-04
CA2593427C (en)	2011-11-29
PT1808168E (pt)	2009-08-25
DOP2006000008A (es)	2006-08-31
SG189762A1 (en)	2013-05-31
HK1100353A1 (en)	2007-09-21
US20100137293A1 (en)	2010-06-03
CN102218141A (zh)	2011-10-19
DK1808168T3 (da)	2009-10-05
US8198232B2 (en)	2012-06-12
EA200701469A1 (ru)	2008-02-28
US8003597B2 (en)	2011-08-23
PT1758565E (pt)	2009-08-19
US20100286168A1 (en)	2010-11-11
US7803754B2 (en)	2010-09-28
GT200600004A (es)	2006-09-11
WO2006076231A8 (en)	2006-09-21
EP2322152A1 (en)	2011-05-18
HRP20090403T4 (hr)	2012-12-31
JP2011184458A (ja)	2011-09-22
AR052082A1 (es)	2007-02-28
JP2008526235A (ja)	2008-07-24
JP4221444B2 (ja)	2009-02-12
CY1109260T1 (el)	2014-07-02
US8022034B2 (en)	2011-09-20
US20060154866A1 (en)	2006-07-13
AU2009202900A1 (en)	2009-08-06
AU2006205164B2 (en)	2011-09-08
DE602006007093D1 (de)	2009-07-16
ATE431139T1 (de)	2009-05-15
US20100291589A1 (en)	2010-11-18
ATE432693T1 (de)	2009-06-15
EP1997484A2 (en)	2008-12-03
HN2006000971A (es)	2011-12-27
TW200637534A (en)	2006-11-01
DK1758565T4 (da)	2013-02-04
NZ578504A (en)	2011-02-25
SI1758565T1 (sl)	2009-10-31
US20100285495A1 (en)	2010-11-11
JP4118323B1 (ja)	2008-07-16
JP4912349B2 (ja)	2012-04-11
DE602006006765D1 (de)	2009-06-25
KR20070095400A (ko)	2007-09-28
NZ556219A (en)	2010-09-30
NO331089B1 (no)	2011-10-03
EP2322151A3 (en)	2012-01-18
US20100298333A1 (en)	2010-11-25
US7803753B2 (en)	2010-09-28
NI200700174A (es)	2008-05-09
NO20101746L (no)	2007-09-27
NZ587368A (en)	2011-01-28
JP4787804B2 (ja)	2011-10-05
PE20061116A1 (es)	2006-10-12
JP2012017330A (ja)	2012-01-26
US20100286172A1 (en)	2010-11-11
CA2593427A1 (en)	2006-07-20
WO2006076231A3 (en)	2007-01-18
US20070072804A1 (en)	2007-03-29
EP2322157A1 (en)	2011-05-18
ES2327268T9 (es)	2013-11-12
EP2322156A1 (en)	2011-05-18
AU2009202898A1 (en)	2009-08-06
KR20100129328A (ko)	2010-12-08
JP2008220374A (ja)	2008-09-25
JP2008110964A (ja)	2008-05-15
SI1808168T1 (sl)	2009-10-31
RS51127B (sr)	2010-10-31
KR101016890B1 (ko)	2011-02-22
MX2007008376A (es)	2008-01-11
PL1758565T5 (pl)	2013-03-29
EP2322151A2 (en)	2011-05-18

Publication	Publication Date	Title
DK1758565T3 (da)	2009-09-07	Fremgangsm de til identifikation af GLP-1-sekretionsfremkaldende stoffer
FR2881809B1 (fr)	2007-04-13	Bloqueur de lacet rapide
EP1997271A4 (en)	2014-08-27	SINGLE-SIGN-ON BETWEEN SYSTEMS
FI20055581L (fi)	2007-04-29	Erotusmenetelmä
DK2061746T3 (da)	2013-11-25	Fremgangsmåde til fremstilling af diestere
DK2061803T3 (da)	2019-11-18	Fremgangsmåde til oprensning af fc-holdige proteiner
DK1852430T3 (da)	2019-08-05	Fremgangsmåde til fremstilling af proanthocyanidinoligomer
DE602006020301D1 (de)	2011-04-07	Schnellverbinder
BRPI0813569A2 (pt)	2014-12-23	Método de inspeção.
DK2993233T3 (da)	2019-08-19	Forbedret promoter og en fremgangsmåde til fremstilling af l-lysin ved anvendelse af samme
FI20040011L (fi)	2005-07-08	Menetelmä pintojen käsittelemiseksi
BRPI0810416A2 (pt)	2014-10-14	Método de hidroformação
DK1856024T3 (da)	2008-11-24	Fremgangsmåde til fremstilling af substituerede biphenyler
EP2087842A4 (en)	2012-10-17	IMAGING DEVICE
EP2114870A4 (en)	2011-10-12	SYNTHETIC ION CHANNELS
ITTO20050184A1 (it)	2005-09-23	Connettore rapido
IT1392297B1 (it)	2012-02-24	Proiettore per palcoscenico e gruppo proiettore comprendente detto proiettore per palcoscenico
ITMO20050254A1 (it)	2007-04-07	Gruppo abrasivo
FI20065363A0 (fi)	2006-05-30	Erotusmenetelmä
DK1994138T3 (da)	2014-05-12	Fremgangsmåde til fremstilling af humant g-csf
BRPI0618419A2 (pt)	2016-09-06	retorno rápido
DK1834528T3 (da)	2014-07-14	Fremgangsmåde til fremstilling af gelé-agtige drikke
FI20055246L (fi)	2006-11-25	Verkkojen välinen palveluyhteistoiminta
DE602006000599D1 (de)	2008-04-17	Kochvorrichtung
DK1717311T3 (da)	2013-01-14	Fremgangsmåde til fremstilling af lactoperoxidase